

Eligibility



Eligibility Criteria

The British Association of Dermatologists (BAD) recommend that **all psoriasis patients** in the UK should be registered with us. The following is our eligibility criteria.



Chronic plaque or generalised pustular psoriasis



Written informed consent



Under care of a dermatologist

Treatments

Patients must be **starting or switching to** one of these drugs, **for treatment of their psoriasis**, in the **last 6 months** to be eligible:



CONVENTIONAL

- ✓ Acitretin
- ✓ Ciclosporin
- ✓ Fumaric acid esters
- ✓ Hydroxycarbamide
- ✓ Methotrexate
- ✓ Systemic oral PUVA

BIOLOGIC

- ✓ Amgevita (adalimumab)
- ✓ Bimzelx (bimekizumab)
- ✓ Cosentyx (secukinumab)
- ✓ Hulio (adalimumab)
- ✓ Humira (adalimumab)
- ✓ Hyrimoz (adalimumab)
- ✓ Idacio (adalimumab)
- ✓ Ilumetri (tildrakizumab)
- ✓ Skyrizi (Risankizumab)
- ✓ Spevigo (spesolimab)
- ✓ Stelara (ustekinumab)
- ✓ Tremfya (guselkumab)
- ✓ Yuflyma (adalimumab)

SMALL MOLECULE

- ✓ Sotyktu (deucravacitinib)
- If a patient has prior exposure to biologic and starting Sotyktu they will enter the biologic exposed cohort.

PASI and DLQI



Conventional patients must have a **PASI of 10 or more** and a **DLQI of 11 or more** (unless switching between conventional therapies). There is no minimum score for biologic or small molecule patients (but we still require a PASI and DLQI).

Patients entering either the small molecule or conventional cohorts must be naive to biologic therapy.

Paediatric Patients



If the patient is **under the age of 16 at the time of consent**, and starting any **systemic treatment for psoriasis**, the patient will be eligible for BADBIR. Conventional patients **do not** need to meet the cDLQI score criteria

